New Biological Drug Development
A
biopharmaceutical drug is more than a protein. UGA Biopharma provides customised Development Services to convert your Drug
Candidate into a New Biological Drug. Our well-established platform technology is based
on a suitable CHO host cell line, an optimized high yield expression vector and
proprietary cell culture media and feeds. UGA Biopharma has successfully
completed a large number of development projects for several international
biopharmaceutical companies.
All you need from one single source in a very short
development time:

We provide:
Cell Line Development read more
Characterization of the new biological drug candidate Gene synthesis and cloning into high yield expression vector Transfection of host cell line Pool generation Single cell cloning Selection of highly productive clones Productivity test Expression stability study Cell bank generation
Upstream Development read more
Lead clone selection Bioprocess optimization to improve productivity and potency Upscale and consistency run in stirred bioreactors
Downstream Development read more
Development of purification methods of cell culture supernatants Optimization of purification methods
Analytics read more
Biosafety testing of cell banks Determination of growth, titer and metabolic data of bioprocesses Analytical assay development Characterization of new biological drug product (e.g.: charge variants, peptide map, N-Glycans, SDS, WB, SEC) Binding and potency assays
Support
Bioprocess transfer Training and after-sales support (on request)
Deliveries
Cell banks with tested performance, stability, scalability and safety Mock cell lines (on request) Cell line development report Cell line biosafety data Cell line stability study USP development data Consistency run DSP development data Analytical data Bioassay data
Our Success
UGA Biopharma successfully completed several development projects.

Contact
UGA Biopharma GmbHNeuendorfstraße 20a
16761 Hennigsdorf
Germany
E-mail: info@ugabiopharma.com
Phone: +49(0)3302 / 2024900